- Home
- CYCU vs NLSP Comparison
CYCU vs NLSP Comparison
Compare CYCU & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCU
- NLSP
- Stock Information
- Founded
- CYCU N/A
- NLSP 2015
- Country
- CYCU United States
- NLSP Switzerland
- Employees
- CYCU N/A
- NLSP N/A
- Industry
- CYCU
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- CYCU
- NLSP Health Care
- Exchange
- CYCU Nasdaq
- NLSP Nasdaq
- Market Cap
- CYCU 13.1M
- NLSP 12.4M
- IPO Year
- CYCU N/A
- NLSP 2021
- Fundamental
- Price
- CYCU $0.39
- NLSP $1.98
- Analyst Decision
- CYCU
- NLSP
- Analyst Count
- CYCU 0
- NLSP 0
- Target Price
- CYCU N/A
- NLSP N/A
- AVG Volume (30 Days)
- CYCU 3.5M
- NLSP 275.4K
- Earning Date
- CYCU 08-15-2025
- NLSP 08-05-2025
- Dividend Yield
- CYCU N/A
- NLSP N/A
- EPS Growth
- CYCU N/A
- NLSP N/A
- EPS
- CYCU N/A
- NLSP N/A
- Revenue
- CYCU $17,398,680.00
- NLSP N/A
- Revenue This Year
- CYCU N/A
- NLSP N/A
- Revenue Next Year
- CYCU N/A
- NLSP N/A
- P/E Ratio
- CYCU N/A
- NLSP N/A
- Revenue Growth
- CYCU N/A
- NLSP N/A
- 52 Week Low
- CYCU $0.26
- NLSP $1.30
- 52 Week High
- CYCU $10.99
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- CYCU N/A
- NLSP 38.01
- Support Level
- CYCU N/A
- NLSP $2.10
- Resistance Level
- CYCU N/A
- NLSP $2.22
- Average True Range (ATR)
- CYCU 0.00
- NLSP 0.14
- MACD
- CYCU 0.00
- NLSP -0.04
- Stochastic Oscillator
- CYCU 0.00
- NLSP 2.00
About CYCU Cycurion Inc. Common Stock
Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.